New Heart Failure Device Pilot Results Published
A new cardiac device for patients with heart failure shows initial feasibility in a recently published 35-patient trial.
Updated on Oct. 22, 2026 in Heart Disease
Live Poll
Do you believe new medical device technologies generally offer better outcomes for heart failure patients?
VisCardia has published results from its 35-patient RECOVER-HF pilot trial for a new heart failure device, the VisONE system. The study establishes the feasibility of using a sham-controlled design for the therapy as the company moves toward a pivotal trial for patients with chronic heart failure.
Why it matters
The pilot study helps refine the design of ongoing trials to test if this device can effectively support patients with reduced heart function. It marks a critical step as the technology moves toward potential FDA approval for heart failure management.
The RECOVER-HF pilot trial utilized a randomized, double-blinded, sham-controlled design involving 35 patients to test the VisONE system. While this small trial establishes feasibility, clinical efficacy remains under investigation in the currently enrolling pivotal trial.
The players
VisCardia
A medical device company that develops innovative therapies for heart failure and has received FDA Breakthrough Device Designation for its VisONE system.
JACC: Heart Failure
A prominent peer-reviewed medical journal that publishes original research and clinical studies on the diagnosis and treatment of cardiovascular conditions.
The details
The VisONE system functions by providing electrical stimulation to the left hemi-diaphragm that is synchronized with the cardiac cycle. This process is intended to assist heart function in patients with chronic heart failure. The device is implanted through a minimally invasive, two-port laparoscopic approach.
Timeline
October 22, 2026: Publication of the RECOVER-HF pilot trial results.
Health Landscape
This development sits within the broader landscape of cardiac rhythm management and supportive device therapy. It follows an industry-wide trend of leveraging FDA Breakthrough Device Designation to accelerate the development of novel interventions for chronic heart failure.
If you are managing chronic heart failure with an ejection fraction of 40% or less, you may want to speak with your cardiologist about emerging clinical trial opportunities. These trials are currently active at up to 30 sites nationwide to evaluate the safety and effectiveness of new implanted therapies.
The takeaway
This pilot trial marks progress in evaluating a new mechanical approach to supporting the heart. Patients living with heart failure should continue to discuss standard care options with their physician while following updates on device-based therapy research.
Further reading
For more information on current treatment trends, visit our Heart Disease section.
Live Poll
Do you believe new medical device technologies generally offer better outcomes for heart failure patients?
